ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Prevalence and determinants of polypharmacy among cancer patients: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines.ESMO open · 2021Guideline
- Outcomes of deprescribing interventions in older patients with life-limiting illness and limited life expectancy: A systematic review.British journal of clinical pharmacology · 2020Pooled it
- Trial
- Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment.The oncologist · 2022Trial
- Application of a person-centered prescription model improves pharmacotherapeutic indicators and reduces costs associated with pharmacological treatment in hospitalized older patients at the end of life.Frontiers in public health · 2022Trial
- Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers.Journal of geriatric oncology · 2018Trial
- Deprescribing opportunities for patients with advanced non-small cell lung cancer: an observational study of potentially inappropriate medications and stakeholders' perspectives.International journal of clinical pharmacy · 2026Observational
- Article
- Changing practice through the art of palliative care - An infographic guide.Future healthcare journal · 2026Article
- Antithrombotic therapy at the end-of-life-continue or stop?Research and practice in thrombosis and haemostasis · 2026Review
- Approaches to deprescribing cardiovascular medications in patients receiving palliative care: a scoping review.Clinical hypertension · 2026Review
- Perceptions of deprescribing for patients with limited life expectancy in primary care.Primary health care research & development · 2025Article
- Current Status of Drug Prescribing among Older Adults with Advanced-stage Cancer Receiving Home Medical Care in Japan: A Nationwide Study.JMA journal · 2025Article
- Real-world patterns of cardiovascular medication use in the final 28 days of life among patients with advanced cancer: a retrospective analysis by hospice care type.BMC palliative care · 2025Article
- Tools for Evaluating Potentially Inappropriate Medication Use in Older Adults: A Scoping Review Assessing Suitability for Register-Based Research.Basic & clinical pharmacology & toxicology · 2025Article
- The impact of palliative care consults on medicines optimisation for patients with cancer referred to hospice care at the end of life: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Impact of the deprescribing timing on medicines optimisation in older cancer patients receiving hospice care at the end of life: a comparative cohort study.European geriatric medicine · 2025Observational
- Pharmacist-led deprescribing interventions for cancer patients in a specialist palliative care setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrent data suggests that potentially inappropriate medicines (PIMs) are common in palliative cancer patients; however, there is a lack of criteria to assist clinicians in identifying PIMs in these patients. The aims of this study were to design and validate a deprescribing guideline for palliative cancer patients and to undertake a descriptive analysis of the identified PIMs.
methodsThis prospective, non-interventional cohort study consisted of four major stages: developing an 'OncPal Deprescribing Guideline' from current evidence, the prospective recruitment of consecutive palliative cancer inpatients with an estimated <6-month prognosis, the assessment of all medications to identify PIMs using both a panel of medical experts without access to the guideline as well as a Clinical Pharmacist independently using the OncPal Deprescribing Guideline and the evaluation of the guideline by testing concordance. Descriptive data on the incidence of PIMs identified were also assessed.
resultsA total of 61 patients were recruited. The OncPal Deprescribing Guideline matched 94% of 617 medicines to the expert panel with a Kappa value of 0.83 [95% CI (0.76, 0.89)] demonstrating an 'outstanding' concordance. Forty-three (70%) patients were taking at least one PIM, with 21.4% of the total medicines assessed identified as PIMs. The medication-associated cost per patient/month was AUD$26.71.
conclusionA guideline to assist in the de-escalation of inappropriate medications in palliative cancer patients was developed from current literature. The OncPal Deprescribing Guideline was successfully validated, demonstrating statistically significant concordance with an expert panel. We found that the incidence of PIMs was high in our patient group, demonstrating the potential benefits for the OncPal Deprescribing Guideline in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.